← Back to Clinical Trials
Recruiting NCT05336318

NCT05336318 Peer2Me: A Peer Supported Program for Adolescent and Young Adult Cancer Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05336318
Status Recruiting
Phase
Sponsor University of Leipzig
Condition Cancer
Study Type INTERVENTIONAL
Enrollment 180 participants
Start Date 2021-01-01
Primary Completion 2024-06-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 39 Years
Study Type INTERVENTIONAL
Interventions
Peer support

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 180 participants in total. It began in 2021-01-01 with a primary completion date of 2024-06-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The present bicentric study has the aim to investigate the effectiveness of the peer supported mentoring program 'Peer2Me' with regard to psychosocial parameters using a prospective Comprehensive Cohort Design. Over a period of three months, acutely ill patients in the intervention group are accompanied by a mentor with the same disease and of similar age. Patients in the control group receive a one-time consultation. Before and after the intervention, mentors and mentees are interviewed about their psychosocial distress and quality of life.

Eligibility Criteria

Inclusion Criteria: * Cancer disease between the ages of 18 and 39 (all tumor entities) * completion of acute treatment at least 2 years ago (mentors) * curative prognosis * Native language German or fluent German speaker * first cancer diagnosis in the last 6 months (mentees, all tumor entities) * curative prognosis Exclusion Criteria: * existing and already diagnosed psychiatric disease, ongoing psychotherapy and/or existing suicidal tendency * palliative treatment approach

Contact & Investigator

Central Contact

Diana Richter, PhD.

✉ diana.richter@medizin.uni-leipzig.de

📞 +493419715438

Principal Investigator

Diana Richter, PhD.

PRINCIPAL INVESTIGATOR

Universitätsklinikum Leipzig

Frequently Asked Questions

Who can join the NCT05336318 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 39 Years, studying Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05336318 currently recruiting?

Yes, NCT05336318 is actively recruiting participants. Contact the research team at diana.richter@medizin.uni-leipzig.de for enrollment information.

Where is the NCT05336318 trial being conducted?

This trial is being conducted at Leipzig, Germany, Hamburg, Germany.

Who is sponsoring the NCT05336318 clinical trial?

NCT05336318 is sponsored by University of Leipzig. The principal investigator is Diana Richter, PhD. at Universitätsklinikum Leipzig. The trial plans to enroll 180 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology